Dubai, December 2020

New Study Shares Treatment Success in Autism Spectrum Disorders – Is There Light at The End of The Tunnel?

Kids Neuro Clinic and Rehab Center, Dubai announces today groundbreaking findings of a new research study on the treatment of Autism Spectrum Disorder (ASD) in younger children.

The results, published in the international, peer-reviewed journal, Neuropsychiatric Disease and Treatment, share breakthrough findings in ASD research. For the first time in medical literature, researchers describe a complete resolution of ASD core signs and symptoms using a combination of FDA approved pharmacological medications and standard supportive therapies.

Autism spectrum disorder (ASD) is a lifelong debilitating neurodevelopmental disorder characterized by repetitive and restricted patterns of behavior, difficulties with communication and social interaction.

Worldwide, the prevalence of ASD is increasing at an alarming rate yet understanding causes of ASD still at large remain unclear. It is well documented however, that care and management for ASD patients has a significant socioeconomic toll impact consistently across the globe.

Due to limitations of published data on costs of ASD patient management locally, a review of published data in the United States of America, where ASD affects one in 59 children, showed societal costs of managing ASD in 2015 were a staggering $268 billion. This figure, which had increased more than six-fold since 2006, is further estimated to rise to $461 billion by 2025 following existing treatment approaches. This data highlights the critical need for progressing knowledge to support ASD treatment and management.

Currently, ASD is considered to be a non-curable disorder. As stated in the National Institute of Neurological Disorders and Stroke (NINDS, USA) fact sheet for ASD, “There is no cure for ASD. Therapies and behavioral interventions are designed to remedy specific symptoms and can improve those symptoms.” [1]

However, recent findings published by Dr. Hamza Alsayouf at the Kids Neuro Clinic and Rehab Center in Dubai, provide promising hope. This pivotal study shares data which reveals pharmacological intervention resulted in an absolute and complete resolution of ASD core signs and symptoms in younger children aged four and older. [2]

In this study, 18 children diagnosed with ASD were successfully treated following treatment protocols developed by the Dubai Healthcare City based center, using risperidone and aripiprazole. Both drugs, which are US Food and Drug Administration (FDA) approved, are used for the treatment of challenging behaviors such as irritability, aggression, and self-injury that coexist with ASD in children aged five and above. The findings reported in this study include ten patients (56%) showing unprecedented complete resolution of their core ASD signs and symptoms, while the remaining eight patients (44%) exhibiting significant improvements in their symptoms ranging from 60 to 80%. Furthermore, these improvements were reported stable with no regression observed during the follow-up period.

These breakthrough findings are the result of Dr Hamza Alsayouf, Director of Kids Neuro Clinic and Rehab Center dedicated and long-term commitment to advance knowledge on the use of pharmacological intervention in ASD. “We are extremely pleased our research is being published at an international platform. This is an area of much-needed focus. This study shows for the first time that, against the prevailing opinion, ASD signs and symptoms can indeed be completely resolved,” said Dr. Alsayouf. He further added, “While we have many video testimonials for ASD children who have been treated successfully at our center over the years, our aim was to ensure our impressive results are published in reputable scientific literature to substantiate our experience in the treatment of ASD.”

This retrospective study expands the evidence-based use of FDA-approved medications that have been available for many years and believed only be effective in managing behavioral issues. “Based on our extensive center experience and applying in-depth scientific evidence, we have demonstrated that use of these medications can help to target the core signs and symptoms of ASD, and not just to treat behavioral issues. We strongly believe that ASD is neuropsychiatric in nature, shares many features with other neuropsychiatric diseases and needs to be approached the same way,” said Dr. Alsayouf.

“We have found chronic use of these medications for more than one to two years is key as well as individualizing treatment plans. Finding the optimal combination and tailoring doses of medications for each patient following a personalized approach is crucial and it is imperative to optimize overall patient outcome. As this study shows, when indicated, the use of ADHD medications in addition to antipsychotic medications helped control ADHD symptoms and boost attention which plays a major role in the learning process.” added Dr. Alsayouf.

In the study, Dr. Alsayouf provided a treatment algorithm and explained every patient’s treatment journey, with the hope to stimulate further controlled clinical research.

This study shows that early tailored pharmacological intervention along with early intervention standard supportive therapies can successfully treat core signs and symptoms in younger ASD patients. It is anticipated that a double-blinded, placebo-controlled study will be performed to validate these findings and further support development of a cure for this chronic and devastating disorder.

As Dr. Alsayouf concluded, “While it may take us decades to uncover the underlying causes of ASD, this should not divert our attention away from treating this debilitating condition from what we know today. We believe our case series will prove to be a big eye-opener.”

English Video summary:

Arabic Video summary:

About Dr. Hamza A Alsayouf, MD

Dr. Alsayouf is an American Board-certified Pediatric Neurologist who completed his training at Nationwide Children’s Hospital, Ohio State University, from 2006–2009. He is the founder and owner of the Kids Neuro Clinic and Rehab Center at Dubai Healthcare City, Dubai, UAE.

About the Journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed and open-access journal, (5-year impact factor, 2.6) reporting on clinical therapeutics and pharmacology research on a range of neuropsychiatric and neurological disorders.

About the Study Center

Kids Neuro Clinic and Rehab Center is a pediatric neurology clinic and pediatric rehabilitation center located in Dubai Healthcare City. The Center is the first independent pediatric neuroscience facility in Dubai that specializes in child neurology and child rehabilitation.

Kids Neuro Clinic and Rehab Center intends to publish further research in this area and encourages interest from individuals and industry wishing to collaborate in its ASD research program.


For more information, please contact:
Dr. Hamza Alsayouf
Tel: 0097145570326


اضطراب طيف التوحد.. هل هناك بصيص أمل ؟

أعلنت عيادة ومركز كدز نيورو في مدينة دبي الطبية عن نتائج مبشرة لدراسة جديدة حول علاج طيف التوحد . ولقد تم نشر هذه الدراسة في مجلة طبية عالمية مرموقة . حيث ولأول مرة في المجال الطبي يتم علاج أعراض اضطراب طيف التوحد بشكل تام باستخدام أدوية معتمدة من إدارة الغذاء والدواء الأمريكية حسب بروتوكولات علاجية تم تطويرها من قبل الدكتور حمزة السيوف .

اضطراب طيف التوحد بشكل عام هو اضطراب نفسي عصبي يتميز بأنماط سلوك متكررة وصعوبات في التواصل الاجتماعي .

وتتزايد نسبة التوحد في جميع أنحاء العالم بمعدل ينذر بالخطر مع عدم فهم سبب هذا الاضطراب.

إن الرعاية لمرضى التوحد لها تأثير وعبئ اقتصادي واجتماعي باهظ، فبحسب البيانات المنشورة في الولايات المتحدة الامريكية حيث هناك طفل منكل 59 طفل مصاب بالتوحد.بلغت تكاليف العلاج والاهتمام بمرضى التوحد 268 مليار دولار في عام 2015 ومن المقدر أن ترتفع تلك التكلفة إلى 461 مليار دولار بحلول عام 2023 وتظهر هذه البيانات الحاجة الماسة لوجود علاج لهذا الاضطراب مجهول السبب.

في الوقت الراهن فإن مرض التوحد يعتبر مرض غير قابل للشفاء , فبحسب المعهد الوطني للأضطرابات العصبية والسكتة الدماغية في الولايات المتحدة الأمريكية لايوجد علاج لمعالجة الاعراض الأساسية للتوحد وقد تحسن التدخلات السلوكية هذه الأعراض.

ومع ذلك فإن النتائج الأخيرة التي نشرها الدكتور السيوف في مركز كيدز نيورو- دبي، قد تشكل بصيص أمل حيث أظهرت الدراسة أن التدخل الدوائي أدى إلى اختفاء أعراض مرضى التوحد تماما في 56% من الأطفال الذين تم علاجهم، ففي هذه الدراسة تم علاج 18 طفل مصاب بالتوحد باستخدام رسبردون او ازبيزازول مع أدوية مستخدمة لعدم القدرة على التركيز حسب بروتوكولات علاجية تم تطويرها من قبل الدكتور السيوف حيث أن 10 أطفال اختفت لديهم أعراض التوحد تماما و8 اطفال تراوحت نسب التحسن لديهم بين 60-80%.

وحول هذه النتائج غير المسبوقة صرح الدكتور السيوف "نحن سعداء بأن هذه الدراسة تم نشرها في مجلة عالمية مرموقة فعلى عكس الرأي السائد بأن مرض التوحد لايمكن شفاءه فأن نتائج هذه الدراسة أظهرت بأنه يمكن علاج مرض التوحد وأضاف الدكتور السيوف "على الرغم من وجود العديد من شهادات الفيديو لأطفال التوحد الذين تم شفاءهم بنجاح في مركز كدز نيورو فقد حرصنا على نشر هذه الدراسة عسى أن تكون نواة لدراسات أشمل من أجل ايجاد حل لهذا المرض المستعصي" ويضيف الدكتور السيوف "استنادا إلى خبرتنا الواسعة في علاج التوحد وبحسب الأدلة العلمية والدراسات الحديثة فقد أثبتنا أنه يمكن علاج مرضى التوحد باستخدام الأدوية بالاضافة إلى العلاج السلوكي كأي مرض نفسي عصبي فهو يشترك بالعديد من السمات مع الأمراض النفسية ويجب معالجتها بنفس الطريقة".

ويعزو الدكتور حمزة السيوف نجاحهم في علاج التوحد إلى الأسباب التالية:

علاج اضطراب التوحد باعتباره مرض نفسي عصبي واستخدام نفس الأدوية لهذه الأمراض.

الاستخدام المزمن لهذه الأدوية

استخدام أدوية عدم القدرة على التركيز بالإضافة إلى رسبردون او ازبيزازول

استخدام خطة علاجية لكل طفل تتوافق مع الاعراض وتعدل حسب استجابته لهذه الادوية.

واختتم الدكتور السيوف "بينما قد يستغرق الامر عقودا لمعرفة السبب الكامن وراء طيف التوحد فإن ذلك يجب أن لا يصرف انتباهنا عن علاج هذا المرض المستعصي بما نعرف اليوم وبالأدوية المتاحة حاليا ونأمل أن تكون هذه الدراسة النواة لدراسات عالمية موسعة".

لمشاهدة ملخص الدراسة

للاطلاع على المقال

د. حمزة أحمد السيوف. إستشاري طب أعصاب الأطفال

  • Pediatric Neurologist American Board interview at Dubai TV ,Dr Hamza Alsayouf

    Dr. Hamza Ahmad Alsayouf is a consultant child neurologist who did his training at Nationwide Children’s Hospital, Ohio State University, 2006-2009.

    He worked as Child neurologist at Mercy Medical Hospital in Des Moines, IA from 2009 to 2012 and was an assistant professor at Des Moines Osteopathic School of Medicine.He joined Mafraq hospital in Abu Dhabi, UAE as a consultant child neurologist and was a core faculty at Gulf Medical University (GMU) from 2012 to 2013.

    He did his Pediatric training at Texas Tech University at Amarillo, Texas, 2002-2005 and his medical school at Jordan University of Science and Technology, 1993-1999.

    Dr. Hamza Ahmad Alsayouf has a mini-fellowship in neuroradiology done at American Academy of Radiology. Dr. Hamza Ahmad Alsayouf is currently American board certified in pediatrics and in child neurology.

  • Dr. Hamza Ahmad Alsayouf

  • Abu Dhabi TV interview with Dr Hamza Alsayouf Pediatric Neurologist

  • Dr. Mahasin Khamis Kid Speech Therapist, KidsNeuro and Rehab Center Dubai

  • Alsharjah Tv Dr Hamza | Pediatric Neurologist Dubai | Child Neurology

  • Dr. Jisha George pediatric physical therapist, KidsNeuro Rehab Center

  • Dr. Marisa Lobo, Counsellor Psychologist, KidsNeuro Rehab Center, Dubai

  • kidsNeuro and Rehab Center is a pediatric neurology clinic and rehabilitation center Dubai

  • Child Neurologist in Dubai - Kids Pediatrics and Neurology UAE

  • Interview of Dr. Hamza Ahmad Alsayouf Pediatric Neurologist Dubai, Part 1

  • A study on the reasons for the lack of children's concentration

  • Orbits tablets ideal way in education and reading | Pediatric Neurologist Dubai | Dr Hamza

  • Interview of Dr Hamza Ahmad Alsayouf Pediatric Neurologist Dubai, Part 2

  • Interview of Dr. Hamza Ahmad Alsayouf Pediatric Neurologist Dubai, Part 3

  • Dr Alsayouf Interview On Alarabiya On April 5 2016 | Pediatric Neurologist Dubai | Child Neurology

  • Challenging Cases in Child Neurology Dubai - Pediatric Neurologist Dubai - Child Neurology

  • Amazing Physical Therapy Package

Our Insurance Partner